Capital Health’s Center for Neuro-Oncology, part of Capital Institute for Neurosciences and the Capital Health Cancer Center, continues to demonstrate nationally the program’s leadership and commitment to clinical excellence. Recently, the Center’s neurosurgical director, Dr. Navid Redjal, led publication of guidelines for the treatment of brain tumors, in addition to announcing the participation of Capital Health in two new immunotherapy trials for glioblastoma patients.
Dr. Redjal, who runs the program’s multi-disciplinary Brain Tumor Clinic, as well as the program’s weekly brain tumor board where patient’s care plans are all reviewed by a multi-disciplinary team of experts, was lead author on a recently published paper discussing updated evidence-based guidelines for treating brain tumors in the Journal of Neuro-Oncology.
Capital Health also recently added two new immunotherapy trials, being run by the National Cancer Institute as part of its clinical trial research program. Both trials involve immunotherapy drugs ipilimumab and nivulomab in treating glioblastoma.
Clinical trials offer patients some of the very latest in care while giving physicians and researchers the opportunity to study the safety and effectiveness of new treatments. Participation is voluntary.
Learn more about our Center for Neuro-Oncology at www.capitalneuro.org.
PHOTO CAPTION: Navid Redjal, MD, FAANS